Drugs used to treat cardiovascular disease as well as those used in the treatment of multiple
other conditions can occasionally produce exaggerated prolongation of the QT interval on …

The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is develo** and
validating a mechanistic‐based assessment of the proarrhythmic risk of drugs. CiPA …

Tissue engineering using cardiomyocytes derived from human pluripotent stem cells holds a
promise to revolutionize drug discovery, but only if limitations related to cardiac chamber …

The implementation of the ICH S7B and E14 guidelines has been successful in preventing
the introduction of potentially torsadogenic drugs to the market, but it has also unduly …

Abstract Introduction The Comprehensive in vitro Proarrhythmia Assay (CiPA) is intended to
address the misidentification of drug-associated torsade de pointes risk based solely on …

Drug‐induced long QT syndrome has resulted in many drugs being withdrawn from the
market. At the same time, the current regulatory paradigm for screening new drugs causing …

Background: Drug-induced QT interval prolongation, a risk factor for life-threatening
ventricular arrhythmias, is a potential side effect of many marketed and withdrawn …

Rationale: Drug-induced proarrhythmia is so tightly associated with prolongation of the QT
interval that QT prolongation is an accepted surrogate marker for arrhythmia. But QT interval …

The US Food and Drug Administration (FDA) Division of Applied Regulatory Science
(DARS) moves new science into the drug review process and addresses emergent …

Background Levoketoconazole is a ketoconazole stereoisomer in development for treatment
of Cushing's syndrome and has not been assessed previously in a clinical trial in patients …